Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TABLE: In turbulent week, 2 IPOs price, 6 test waters

This article was originally published in Scrip

Executive Summary

While the biotechnology industry continues to debate whether the window for initial public offerings is closing, two drug developers priced IPOs during a US stock trading week shortened by the July 4th holiday and six revealed their plans to become public companies.

You may also be interested in...



IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle

Intellia Therapeutics Inc. sold more shares in its initial public offering than originally expected and the CRISPR/Cas9 specialist did so at the top of its proposed price range, proving that investors remain excited about gene editing, but have less enthusiasm for other early-stage therapeutics firms.

BMS Makes The Case For A Lasting Hematology Legacy

Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.

Biohaven’s Migraine Empire Expands As Zavegepant Conquers Phase III

The company will seek US FDA approval after intranasally administered zavegepant passes its second pivotal test in the treatment of migraine attacks, followed by ex-US approvals with partner Pfizer. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC025736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel